Compare AZZ & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | IRTC |
|---|---|---|
| Founded | 1956 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 1994 | 2016 |
| Metric | AZZ | IRTC |
|---|---|---|
| Price | $133.55 | $122.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $126.00 | ★ $197.92 |
| AVG Volume (30 Days) | 131.5K | ★ 393.4K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 9.97 | N/A |
| Revenue | ★ $1,061,817,000.00 | $747,138,000.00 |
| Revenue This Year | $5.47 | $19.60 |
| Revenue Next Year | $6.13 | $15.94 |
| P/E Ratio | $13.44 | ★ N/A |
| Revenue Growth | 14.53 | ★ 26.24 |
| 52 Week Low | $74.00 | $97.16 |
| 52 Week High | $141.18 | $210.01 |
| Indicator | AZZ | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 50.09 |
| Support Level | $130.88 | $119.48 |
| Resistance Level | $141.18 | $124.40 |
| Average True Range (ATR) | 3.62 | 4.97 |
| MACD | 1.01 | 1.61 |
| Stochastic Oscillator | 65.84 | 71.45 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.